Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors

Abstract

Stereotactic ablative radiotherapy (SABR) is effective for thoracic cancer and metastases; however, adverse effects are greater for central tumors. We evaluated factors affecting outcomes and toxicities after SABR for patients with primary lung and oligometastatic tumors.

Keywords

• lung cancer
• radiation
• stereotactic ablative radiotherapy
• stereotactic body radiation therapy
• survival outcomes
• toxicity